RxDoctor Payments Data

Jamie Holder

Psychiatric/Mental Health · Fredericksburg, VANPI 1447905856

Payments from drug & device makers

$2,096in general payments, 2019–2025

Across 133 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$344
  • Otsuka America Pharmaceutical, Inc.$302
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$298
  • AbbVie$252
  • Takeda Pharmaceuticals U.S.A., Inc.$238
  • Vanda Pharmaceuticals Inc.$139
  • plus $522 from 9 others

What the payments were for

  • Food & beverage$2,04197%
  • Education$553%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,096 in reported general payments places this provider in the 80th percentile of 1,003 psychiatric/mental health providers in Virginia.

See all psychiatric/mental health providers in Virginia

Medicare billing

Part B allowed, 2024
$18,765
Medicare patients
50
Services billed
214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine12$58,572
RexultiBrexpiprazole21$51,687
VraylarCariprazine Hcl20$28,652
Aripiprazole55$6,801
VyvanseLisdexamfetamine Dimesylate12$4,832
Desvenlafaxine Succinate ErDesvenlafaxine Succinate24$1,890
Bupropion XlBupropion Hcl69$1,724
Duloxetine Hcl63$1,578
Venlafaxine Hcl ErVenlafaxine Hcl36$1,277
Prazosin Hcl36$1,194
Fluoxetine Hcl86$1,114
Buspirone Hcl57$1,102
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine30$1,042
Divalproex Sodium11$828
Hydroxyzine Hcl31$802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$23$58,57212 claims
Otsuka America Pharmaceutical, Inc.Rexulti$302$51,68721 claims
AbbVieVraylar$252$28,65220 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$238$4,83212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,003 psychiatric/mental health providers in Virginia.

Other psychiatric/mental health in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →